Cable Hill Partners, LLC Editas Medicine, Inc. Transaction History

Cable Hill Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 06, 2019	SELL	$20.48 - $27.76 $5,120 - $6,940	-250 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$19.43 - $26.41 $3,886 - $5,282	200 Added 400.0%	250 $6,000
Q2 2018 Aug 03, 2018	SELL	$31.4 - $41.01 $6,280 - $8,202	-200 Reduced 80.0%	50 $2,000
Q1 2018 Apr 20, 2018	SELL	$29.84 - $44.08 $2,984 - $4,408	-100 Reduced 28.57%	250 $8,000
Q4 2017 Feb 22, 2018	BUY	$21.89 - $31.34 $3,940 - $5,641	180 Added 105.88%	350 $12,000
Q2 2017 Aug 14, 2017	BUY	N/A	170	170 $3,000

228

54.7M

425K

306K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $94.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Cable Hill Partners, LLC with notifications on news.